Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexanolone for Stress-induced Alcohol Use in PTSD
NCT05223829Phase 1Active, not recruiting
- Sponsor
- Yale University
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brexanolone in post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD), sponsored by Yale University. Primary endpoints: Treatment-emergent adverse events at 30 days and Percentage of milliliters consumed during ad-libitum drinking. Started Aug 2023; status: active, not recruiting.
02
Drugs
brexanolone
03
Conditions
post-traumatic stress disorder (PTSD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05223829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223829.